« Back Journal of Dermatological Science

Article in Press

Aberrant DNA methylation in skin diseases

  • Yaping Li

      Affiliations

    • Department of Dermatology and Epigenetic Research Center, Second Xiangya Hospital, Central South University, 139 Renmin Middle Rd, Changsha, Hunan 410011, China
    • ,
  • Amr H. Sawalha

      Affiliations

    • Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA
    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    • Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
    • ,
  • Qianjin Lu

      Affiliations

    • Department of Dermatology and Epigenetic Research Center, Second Xiangya Hospital, Central South University, 139 Renmin Middle Rd, Changsha, Hunan 410011, China
    • Corresponding Author InformationCorresponding author. Fax: +86 731 5533525.

Received 31 December 2008 ,Revised 16 January 2009 ,Accepted 29 January 2009. Published online 12 July 2010 Corrected Proof

References 

  1. Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci. 2002;59:241–257
  2. Vercelli D. Genetics, epigenetics, and the environment: Switching, buffering, releasing. J Allergy Clin Immunol. 2004;113:381–386
  3. van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol. 2005;32:479–487
  4. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol. 2006;155:1154–1158
  5. Takeuchi T, Liang S-B, Ohtsuki Y. Downregulation of expression of a novel cadherin molecule, T-cadherin, in basal cell carcinoma of the skin. Mol Carcinog. 2002;35:173–179
  6. Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H. Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene. 2003;22:5519–5524
  7. Carucci JA, Martinez JC, Zeitouni NC, Christenson L, Coldiron B, Zweibel S, et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004;30:651–655
  8. Murao K, Kubo Y, Ohtani N, Hara E, Arase S. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53pathways. Br J Dermatol. 2006;155:999–1005
  9. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM. P16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol. 2004;122:1284–1292
  10. Tyler LN, Ai L, Zuo C, Fan CY, Smoller BR. Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol. 2003;16:660–664
  11. Zhu F, Xia X, Liu B, Shen J, Hu Y, Person M, et al. IKKa shields 14-3-3σ, a G2/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Mol Cell. 2007;27:214–227
  12. Takeuchi T, Liang SB, Matsuyoshi N, Zhou S, Miyachi Y, Sonobe H, et al. Loss of T-cadherin (CDH13, H-Cadherin) expression in cutaneous squamous cell carcinoma. Lab Invest. 2002;82:1023–1029
  13. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet. 1991;172:262–268
  14. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma.. APMIS. 2007;115:1161–1176
  15. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546–6552
  16. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23:4014–4022
  17. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol. 2006;126:422–431
  18. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, et al. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol. 2007;30:689–694
  19. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol. 2002;161:229–237
  20. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207–211
  21. Worm J, Christensen C, Grønbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene. 2004;23:5215–5226
  22. Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, et al. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int J Oncol. 2004;25:1415–1421
  23. McGuinness C, Wesley UV. Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation. Front Biosci. 2008;13:2435–2443
  24. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 2008;21:545–558
  25. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis. 2005;26:1856–1867
  26. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol. 2004;24:4781–4790
  27. Scarisbrick JJ, Mitchell TJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol. 2003;121:894–901
  28. Zhang Q, Raghunath PN, Vonderheid E, Ødum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells: results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157:1137–1146
  29. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18:1288–1295
  30. Van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG and p73. J Clin Oncol. 2005;23:3886–3896
  31. Jones C, Wain EM, Ferreria S, Orchard GE, Whittaker SJ, Mitchell TJ. Epigenetic silencing of the Fas gene promoter in cutaneous T-cell lymphoma. Br J Dermatol. 2008;158:874–912
  32. Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J, Hoefnagel JJ, Mulder AA, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-Cell lymphoma. J Clin Oncol. 2006;24:296–305
  33. Belaud-Rotureau MA, Marietta V, Vergier B, Mainhaguiet G, Turmo M, Idrissi Y, et al. Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch. 2008;452:607–620
  34. Takino H, Li C, Hu S, Kuo T-T, Geissinger E, Muller-Hermelink HK, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod Pathol. 2008;21:1517–1526
  35. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin K-M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865–5877
  36. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004;64:5527–5534
  37. Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J, et al. Epigenetic loss of the familial tumor suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum Mol Genet. 2004;13:2753–2765
  38. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, et al. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res. 2004;64:2411–2417
  39. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, et al. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer. 2001;94:243–251
  40. Zendman AJ, van Kraats AA, den Hollander AI, Weidle UH, Ruiter DJ, van Muijen GN. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int J Cancer. 2002;97:195–204
  41. Sharma BK, Smith CC, Laing JM, Rucker DA, Burnett JW, Aurelian L. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions. Dermatology. 2006;213:192–199
  42. Guan X, Sagara J, Yokoyama T, Koganehira Y, Oguchi M, Saida T, et al. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer. 2003;107:202–208
  43. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol. 2003;163:683–690
  44. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci. 2004;95:962–968
  45. Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijima T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res. 2005;15:15–20
  46. Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23:9351–9358
  47. Nagasawa T, Zhang Q, Raghunath PN, Wong HY, El-Salem M, Szallasi A, et al. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leuk Res. 2006;30:303–312
  48. Child FJ, Scarisbrick JJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J Invest Dermatol. 2002;118:941–948
  49. Strickland FM, Richardson BC. Epigenetics in human autoimmunity. Autoimmunity. 2008;41:278–286
  50. Chen M, Chen ZQ, Cui PG, Yao X, Li YM, Li AS, et al. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br J Dermatol. 2008;158:987–993
  51. Zhang K, Zhang R, Li X, Yin G, Niu X, Hou R. The mRNA expression and promoter methylation status of the p16 gene in colony-forming cells with high proliferative potential in patients with psoriasis. Clin Exp Dermatol. 2007;32:702–708
  52. Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, Hirankarn N, Mutirangura A . SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med. 2006;84:175–182
  53. Kim YI, Logan JW, Mason JB, Roubenoff R. DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. J Lab Clin Med. 1996;128:165–172
  54. Bowcock AM. The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet. 2005;6:93–122
  55. Nakamura T, Sekigawa I, Ogasawara H, Mitsuishi K, Hira K, Ikeda S, et al. Expression of DNMT-1 in patients with atopic dermatitis. Arch Dermatol Res. 2006;298:253–256
  56. Sreekumar GP, Smyth JR, Ambady S, Ponce de Leon FA. Analysis of the effect of endogenous viral genes in the Smyth line chicken model for autoimmune vitiligo. Am J Pathol. 2000;156:1099–1107
  57. Nakagawa K, Harrison LC. The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev. 1996;152:193–236
  58. Groudine M, Eisenman R, Weintraub H. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature. 1981;292:311–317
  59. Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis. 1992;50:39–42
  60. Luo Y, Li Y, Su Y, Yin H, Hu N, Wang S, et al. Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;159:827–833

PII: S0923-1811(09)00061-9

doi: 10.1016/j.jdermsci.2009.01.009

« Back Journal of Dermatological Science

Article in Press

Article Tools

* Image Usage & Resolution